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Abstract
BACKGROUND—Controversy surrounds the question of whether clinical trial participants have 
better outcomes than comparable patients who are not treated on a trial. We explored this question 
using a recent large, randomized, multi-center study comparing peripheral blood (PB) with bone 
marrow (BM) transplantation from unrelated donors (URD), conducted by the Blood and Marrow 
Transplant Clinical Trials Network (BMT CTN).
METHODS AND FINDINGS—We compared characteristics and outcomes of study participants 
(n=494) and non-participants (n=1384) who appeared eligible and received similar treatment 
without enrolling on the BMT CTN trial at participating centers during the study time-period. Data 
were obtained from the Center for International Blood and Marrow Transplant Research. 
Outcomes were compared between the two groups using Cox proportional hazards regression 
models.
No significant differences in age, sex and disease distribution, race/ ethnicity, HLA matching, 
comorbidities and interval from diagnosis to HCT were seen between the participants and non-
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participants. Non-participants were more likely to have lower performance status, lower-risk 
disease, and older donors, and to receive myeloablative conditioning and anti-thymocyte globulin. 
Non-participants were also more likely to receive PB grafts, the intervention tested in the trial 
(66% vs. 50% p<0.001). Overall survival, transplant-related mortality, and incidences of acute or 
chronic GVHD were comparable between the two groups though relapse was higher (HR 1.22, 
95% CI 1.02–1.46, p=0.028) in non-participants.
CONCLUSION—Despite differences in certain baseline characteristics, survival was comparable 
between study participants and non-participants. The results of the BMT CTN trial appear 
generalizable to the population of trial-eligible patients.
Introduction
Randomized clinical trials (RCT) are considered the gold standard in clinical research. 
However, their applicability to larger populations may be limited because trial patients may 
not be representative of most patients due to selection bias.(1) Despite this potential 
limitation, very few trials have the generalizability of their results assessed, even though 
discussion about generalizability is a quality indicator for RCT reporting within the 
CONSORT guidelines.(2) It is also controversial whether patients enrolled in trials have 
better outcomes than those not enrolled in trials, controlling for biological characteristics. 
While some studies show improved outcomes in trial participants as compared to non-
participants,(3–6) others report no trial effect.(7, 8) Peppercorn et al reported that most 
studies comparing outcomes between trial and non-trial participants failed to control for 
potential confounding factors between the groups, and therefore, available evidence does not 
support a trial effect on outcomes.(9)
The Blood and Marrow Transplant Clinical Trials Network (BMT CTN) conducts 
multicenter trials to improve treatment approaches in hematopoietic cell transplantation 
(HCT). A phase III randomized, multicenter study conducted by BMT CTN (BMT CTN 
0201) between March 2004 and September 2009 compared outcomes after bone marrow 
(BM) and filgrastim mobilized peripheral blood (PB) HCT from unrelated donors (URD).
(10) The trial found no significant difference in survival between the two groups, but a 
significant increase in the risk of chronic graft vs. host disease (GVHD) with PB. Its practice 
changing potential is based on the fact that the study supports the use of BM grafts with 
decreased chronic GVHD, in the current era where PB is used in 70% of URD transplants.
Before applying the study results to clinical practice, it is important to understand their 
generalizability to the universe of potential patients. To do so, we compared the 
characteristics and outcomes of participants in BMT CTN protocol 0201 with those of 
patients receiving unrelated donor HCTs at the same centers during the study time-period 
but who were not study participants, using data from the Center for International Blood and 
Marrow Transplant Research (CIBMTR). We restricted the analysis to centers participating 
in BMT CTN and to patients receiving similar treatment off-protocol in order to minimize 
confounding variables while assessing for a trial effect.
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The CIBMTR is a research collaboration of the Medical College of Wisconsin and the 
National Marrow Donor Program (NMDP)/Be The Match. More than 350 transplantation 
centers worldwide contribute detailed data on consecutive allogeneic and autologous HCT to 
the CIBMTR’s outcomes registry. The CIBMTR also leads the data coordinating center for 
the BMT CTN. Patients are followed longitudinally with yearly follow-up. Compliance is 
monitored by on-site audits. Observational studies by the CIBMTR are performed in 
compliance with the Privacy Rule (HIPAA) as a Public Health Authority and with all 
applicable federal regulations pertaining to the protection of human research participants as 
determined by continuous review of the Institutional Review Board of the NMDP.
The current study included two main cohorts of patients for whom information was retrieved 
from the CIBMTR database: patients treated on the BMT CTN 0201 protocol and patients 
who underwent URD transplants during the study time period at 38 participating centers but 
not on the BMT CTN study. The eligibility criteria for the BMT CTN protocol included age 
<66 years and HCT for acute leukemia, myelodysplasia, chronic myeloid or 
myelomonocytic leukemia or myelofibrosis. Exclusion criteria are included in 
supplementary table 1.
The comparator group of interest was patients who, based on information from the CIBMTR 
database, appeared eligible per the inclusion and exclusion criteria of the BMT CTN study 
and received URD HCT at the participating centers during the time the trial was open, but 
did not enroll in the study. Since not all information needed to determine eligibility for the 
protocol (organ function requirements) was available from the CIBMTR database, we 
selected patients treated with similar regimens to identify a group as close as possible in 
clinical profile to the trial participants. The assumption was that patients able to receive 
regimens used in the clinical trial were likely to have organ function consistent with 
eligibility criteria for the trial.
Study outcomes
We estimated the proportion of all potentially eligible URD transplants that were enrolled on 
the protocol. Survival, relapse, transplant-related mortality (TRM) and occurrence of acute 
and chronic GVHD were compared between the participants and non-participants. TRM was 
defined as death while in complete remission. TRM and relapse were considered competing 
risks where occurrence of one of them prevents occurrence of the other one. Overall survival 
(OS) was calculated as time from transplant to death. Death from any cause was considered 
as an event and surviving patients were censored at the time of last follow-up. Disease free 
survival (DFS) was defined as time from transplant to treatment failure (death or relapse). 
Patients alive in remission were censored at the time of last follow-up.
Statistical analysis
The characteristics of the participants and non-participants in the entire cohort and the 
separate PB and BM subgroups were compared using the chi-square test for categorical 
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variables and the Wilcoxon rank-sum test for continuous variables. Multivariate analyses of 
acute and chronic GVHD, TRM, relapse, DFS and OS were performed using Cox 
proportional hazards regression, using participation in the BMT CTN study as the main 
effect. Variables considered in the multivariate analysis are described in Supplementary 
Table 2. The assumption of proportional hazards was tested for each variable using a time-
dependent covariate, and appropriate adjustments were performed where needed. 
Multivariate models were built using a forward variable selection method. In addition, 
stratified analysis of BM and PB recipients was performed to compare the outcomes of 
BMT CTN 0201 participants versus non-participants within each graft source subgroup 
because the proportion of graft source was significantly different between the study 
participants and non-participants. All P values are 2-sided, and a level of significance 
(alpha) of 0.05 was used throughout. All analyses were performed using SAS Version 9.3 
statistical software (SAS Institute, Cary, NC).
Results
Patient characteristics
Figure 1 shows the selection of patients for this study. A total of 5716 patients received a 
first allogeneic HCT for diseases specified by the BMT CTN 0201 protocol at participating 
transplant centers during the study period. Among these, 2708 were excluded for not 
meeting the trial eligibility criteria. We also excluded 32 participants and 109 non-
participants from 10 centers that had no eligible non-participants for analysis. An additional 
6 patients were excluded because they had not consented for CIBMTR research or had a 
followup <100 days. From the remaining 2893 patients, 1046 received a regimen different 
from what was specified by the BMT CTN 0201 protocol; these patients were excluded 
from further analysis. Five hundred fifty one patients were enrolled on the BMT CTN 0201 
study. In addition to excluding the 32 patients from centers where comparable non-trial 
patients could not be identified, we excluded 25 patients who did not undergo HCT. The 
final study population consisted of 494 patients who participated in the BMT CTN 0201 
study and 1353 patients who appeared to be eligible based on the trial’s inclusion/exclusion 
criteria, did not enroll, and yet received the same conditioning and GVHD prophylaxis 
regimens as trial participants, suggesting that they could have enrolled on the trial. Thus, 
approximately 27% (494/ 494+1353) of apparently eligible patients at participating centers 
were enrolled on the trial. If we instead estimate the participation rate based on all non-
participants without regard to conditioning regimens and GVHD prophylaxis, the trial 
participation rate would be 17% (494/494+1353+1046).
There were no significant differences in the age, sex and disease distribution, race/ ethnicity, 
HLA matching and interval from diagnosis to HCT between the participants and non-
participants. A pretransplant HCT comorbidity index, available for 64% patients, was 
comparable between participants and non-participants. A higher proportion of non-
participants had a Karnofsky performance score (KPS) <90, lower risk disease, and received 
antithymocyte globulin (ATG). PB was used more commonly as the graft source in the non-
participants as compared to the study participants (66% vs. 50%; p<0.001). (Table 1) 
Characteristics of participants and non-participants were also evaluated separately in the 
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groups receiving PB and BM. Among those receiving PB grafts, non-participants were 
older, had more myeloid diseases but comparable disease risk, higher proportion of ≤7/8 
HLA match donors and more frequent use of ATG than the study participants. In the BM 
group, non-participants were younger, more likely to be Hispanic, have low risk disease, 
receive myeloablative conditioning and ATG and less likely to have a KPS ≥90.
Reasons for non-participation
To gain insight into the reasons for non-participation, we reviewed study coordinator 
tracking logs. We identified a group of patients (n=713) who consented to the study, but 
didn’t proceed on the protocol. Among these, 344 patients (48%) had a transplant off 
protocol reported to CIBMTR. Removal from the protocol was mainly for donor related 
issues (n=237, 69%), for example, the donor did not provide consent or was ineligible for 
the study or due to donor center decision. Among transplanted patients removed from the 
trial for a donor reason, 72% received PB grafts. The remaining patients (n=107, 31%) were 
removed because of patient related issues (e.g., patient found to be ineligible or withdrew 
consent). Among these, 84% received PB grafts.
Outcomes of participants vs. non-participants
Compared to the BMT CTN participants, non-participants did not have a significantly 
increased risk of mortality both in the unadjusted analysis (p=0.46) and after adjusting for all 
the clinical variables (HR 1.08, 95% CI 0.94–1.24, p=0.26). (Figure 2A) While TRM was 
comparable between the two groups, relapse was higher (HR 1.22, 95% CI 1.02–1.46, 
p=0.028) resulting in a trend towards lower disease free survival in non-participants (HR 
1.14, 95% CI 1.0–1.3 p=0.05). Center effect was examined and was not found to be 
significant in the multivariate model (p=0.11). No statistically significant differences in 
acute (HR 0.96, 95% CI 0.82–1.12, p=0.57) and chronic GVHD (HR 1.06, 95% CI 0.92–
1.23, p=0.41) were noted between study participants and non-participants. (Table 2)
Although the interaction between trial participation and graft source was not significant 
(p=0.23), we compared OS between study and non-study participants receiving PB and BM 
separately in a secondary analysis. The risk of mortality was not significantly higher for BM 
recipients (HR 1.0, 95% CI 0.80–1.23, p=0.94) or for PB recipients (HR 1.2, 95% CI 0.98–
1.41, p=0.07) in non-participants compared to trial participants. (Figure 2B and 2C) A 
stratified analysis for other clinical outcomes also showed comparable results in BM and PB 
group separately in the participants and non-participants. (Table 3)
Impact of graft source
In the multivariate analysis of OS for the entire cohort with a median follow up of 60 
months for survivors, graft source emerged as a significant predictor with PB associated 
with increased mortality (HR 1.16, 95% CI 1.01–1.32, p=0.02). However when the analysis 
was limited to 2 years post HCT similar to the original report, no difference was observed 
(HR 1.03, 95% CI 0.89–1.19, p=0.64).(10) Similar to the original report, PB was associated 
with a higher incidence of chronic GVHD than BM (HR 1.38, 95% CI 1.2–1.6, p<0.001).
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Concerns have been raised about the generalizability of RCT results due to the questionable 
representativeness of patients enrolled in the trials.(5, 11, 12) Differences in the outcomes of 
patients treated on versus off trials may be due to inclusion of a highly selected patient 
population (based on medical status, disease status or compliance), differences in care due to 
clinical trial participation (e.g., closer follow-up or more precise application of therapies), or 
due to true biological effects.(7, 13, 14) Interestingly, a recent study that compared patients 
on the standard arms of a series of South West Oncology Group phase III cancer clinical 
trials to non-trial control subjects selected from the Surveillance, Epidemiology, and End 
Results program found that the improved OS with trial participation was only seen for the 
first year after diagnosis and evened out in the long- term.(15) In HCT, there is a paucity of 
studies evaluating if the results from RCTs are likely to translate to the general transplant 
population.
In one of the first such studies in HCT, we found that approximately a quarter of the 
potentially eligible patients participated in the randomized study. This is likely an over-
estimate since some potentially eligible patients may have received alternative conditioning 
regimens due to competing protocols or center practices and, thus, were not included in the 
denominator because of our patient selection criteria. Even with the most conservative 
estimate of the participation rate (17%), this is still much better than <10 % participation 
rate that has been reported in other studies.(16, 17) We observed higher proportion of high 
risk disease in the trial participants than the non-participants and comparable distribution of 
age, comorbidities and race/ethnicity which is also different from the pattern reported in the 
literature. Usually, patients from racial/ ethnic minorities or those who are higher risk, older 
and with comorbidities are less represented in clinical trials.(14, 18–20) The fact that we did 
not observe this may be attributed to either the relatively broad inclusion criteria of the 
clinical trial, or to our selection of comparator patients that were healthy enough to be 
potential trial participants based on age and comorbidities. A difference between the 
participants and non-participants was the greater use of ATG in the non-trial participants 
reflecting the standard practice of some centers to use it outside of a clinical trial to decrease 
GVHD with URD transplants.(21, 22)
Despite some differences in the clinical characteristics of patients enrolled on the trial 
compared to those not enrolled, there was no difference in the OS. This may be due to 
similar baseline characteristics between the two groups such as age, disease, interval from 
diagnosis to treatment and HLA match that were associated with lower OS. While a higher 
proportion of the trial non-participants had lower KPS, which was associated with worse 
OS, this may have been counterbalanced by a lower proportion of high risk disease. Our 
results are consistent with what has been reported in systemic reviews that there is no 
definitive evidence for superior outcomes in patients participating in a clinical trial as 
compared to non-participants treated in a similar fashion when adjusted for the confounding 
factors.(9, 23) In addition, it is also possible that HCT patients are treated and followed in 
specialized settings with aggressive supportive care regardless of trial participation leading 
to similar outcomes between participants and non-participants.
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We did observe that relapse was lower and DFS marginally better in trial participants. 
Analyses stratified by graft type showed that this observation is primarily due to increased 
relapse in non-participants compared to participants when PB is used. It is possible that 
more non-participants had unmeasured high risk disease (such as high risk cytogenetics or 
FLT3 mutation positive) not appropriately captured in the risk categorization used for the 
BMT CTN study or the current study. While a higher proportion of non-participants 
received ATG, receipt of ATG was not associated with relapse in our multivariate analysis.
Poorer survival in patients receiving PB grafts as compared to BM grafts in our multivariate 
analysis is different from the results of the BMT CTN study as well as a prior observational 
study which reported comparable OS between PB and BM groups except for the good risk 
CML patients.(24) Since this difference was not detected when the observations were 
limited to 2 years, our findings may be explained by a longer period of follow-up than the 
clinical study (BMT CTN 0201 is currently analyzing their 5 year follow-up data). This 
does, however, potentially add increased evidence that BM should be the default graft 
source.
Our study has some limitations. By applying the inclusion criteria and restricting the non-
trial cohort to those with the same conditioning and GVHD prophylaxis, we aimed to create 
a group that was similar to the trial participants to enhance confidence in the analysis. 
However, it is possible that some ineligible patients on the basis of organ function were 
misclassified as potentially eligible since we did not have detailed information about organ 
function. Conversely, some patients may not have appeared potentially eligible because they 
received different conditioning or GVHD prophylaxis regimens or participated in different 
clinical trials, even though they could have tolerated the treatment specified by the trial. 
These biases would affect the estimate of the percentage of potentially eligible patients that 
ended up on the trial, but in opposite directions. It is also possible that other unmeasured 
differences, such as use of maintenance therapy post HCT or different dosing of busulfan 
were present, but these were not specified in the 0201 protocol either. We also did not study 
patients who received their URD transplants at non- study centers, thereby precluding a truly 
population-based comparison and focusing only on the ‘trial effect’ aspect of 
generalizability. Other facets of generalizability including the difference in outcomes 
between patients treated in a similar fashion at study centers vs. at non-study centers will be 
addressed in subsequent analyses. We do not know the reasons for low trial enrollment, such 
as refusal to participate, investigators not offering the trial to patients, or enrollment on 
competing protocols, due to lack of information for trial non-participation. By restricting the 
treatment regimens to those specified by the study, we were able to select non-trial 
participants who appeared the most comparable to trial participants, based on known 
characteristics.
The strength of our study is that we were able to perform a careful comparison of patients 
who did or did not participate in the trial at the same centers treated in a similar fashion 
during the same time period using a consistent data source. This analysis improves our 
confidence that treatment effects for this particular trial translate to the real-world setting 
and can be extrapolated to future patients who meet the disease and health requirements 
outlined in the trial.
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While consideration of external validity in the design and reporting of randomized clinical 
trials is important, not all studies can do this. Our study was possible because of the 
availability of the CIBMTR database which provides a unique resource of observational data 
to address questions about the generalizability of HCT clinical trials. Such a database can 
also track real-world use of technologies to understand shifts in clinical practice. RCTs are 
unique in providing an unbiased comparison of therapies but are logistically difficult and 
expensive. Gathering the data to support the generalizability of clinical trial results and the 
actual effectiveness of study interventions in practice will help translate the investment in 
time- and resource-intensive studies into clinical practice changes.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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• Compared characteristics and outcomes of BMTCTN 0201participants and non-
participants
• Few differences in baseline characteristics were observed
• Survival was comparable between study participants and non-participants
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(A): Adjusted overall survival in all study participants and non-participants
(B): Adjusted overall survival in study participants and non-participants receiving bone 
marrow graft
(C): Adjusted overall survival in study participants and non-participants receiving PB graft
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Table 1
Characteristics of patients who received a BM or PB transplant between 2004 and 2009 from participating 
centers, according to enrollment status and regimen received a
Characteristics
Patients enrolled and
transplanted on BMT CTN
0201 study
Likely eligible but not
enrolled, transplanted
with same regimen P value b
Number of patients 494 1353
Age at transplant, years 0.73
    0–9 17 (3) 52 (4)
    10–19 34 (7) 107 (8)
    20–49 252 (51) 704 (52)
    >50 191 (39) 490 (36)
Patient gender 0.18
  Male 276 (56) 708 (52)
  Female 218 (44) 645 (48)
Recipient race 0.79
  Caucasian 446 (90) 1232 (91)
  African-American 20 (4) 55 (4)
  Other 28 (6) 66 (5)
Recipient ethnicity 0.06
  Hispanic 19 (4) 92 (7)
  Non-Hispanic 470 (95) 1250 (92)
  Unknown 5 (1) 11 (<1)
KPS 0.03
  >=90 313 (63) 766 (57)
  <90 138 (28) 441 (33)
  Unknown 43 (9) 146 (11)
Sorror comorbidity index 0.48
  0 184 (37) 512 (38)
  1–2 68 (14) 158 (12)
  >=3 62 (13) 198 (15)
  Unknown (info not collected on patients reported prior to 2008) 180 (36) 485 (36)
Disease 0.24
  AML 233 (47) 673 (50)
  ALL 106 (21) 245 (18)
  CML 62 (13) 150 (11)
  MDS/Myelofibrosis/CMML 93 (19) 285 (21)
Disease risk prior to transplantc 0.02
  Low risk 360 (73) 1063 (79)
  High risk 134 (27) 288 (21)
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Characteristics
Patients enrolled and
transplanted on BMT CTN
0201 study
Likely eligible but not
enrolled, transplanted
with same regimen P value b
  Unknown 0 2 (<1)
Secondary leukemia/MDS with prior Auto (> 12 months from 
current transplant)
0.86
  No 489 (99) 1338 (99)
  Yes 5 (1) 15 (1)
Graft type <0.001
  Bone Marrow 247 (50) 456 (34)
  Peripheral Blood 247 (50) 897 (66)
Donor age, years <0.001
  18–29 200 (40) 308 (23)
  30–39 154 (31) 347 (26)
  40–49 114 (23) 200 (15)
  50–61 26 (5) 47 (3)
  Unknown 0 451 (33)
Antigen match at A, B, DRB1 0.13
  8/8 371 (75) 954 (71)
  <=7/8 123 (25) 398 (29)
  Missing 0 1 (<1)
Donor/recipient sex match 0.03
  M/M 208 (42) 486 (36)
  M/F 132 (27) 399 (29)
  F/M 68 (14) 214 (16)
  F/F 86 (17) 239 (18)
  Unknown 0 15 (1)
Donor/recipient CMV match <0.001
  −/− 186 (38) 370 (27)
  −/+ 154 (31) 450 (33)
  +/+ 96 (19) 280 (21)
  +/− 57 (12) 154 (11)
  Unknown 1 (<1) 99 (7)
Conditioning regimen intensity 0.04
  Myeloablative 384 (78) 1119 (83)
  Reduced Intensity 110 (22) 233 (17)
  Unknown 0 1 (<1)
Use of ATG or Campath <0.001
  ATG or Campath 126 (26) 430 (32)
  No ATG or Campath 362 (73) 923 (68)
  Unknown 6 (1) 0
Interval from diagnosis to transplant months, median(range) 8 (<1–168) 9 (<1–357) 0.49
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Characteristics
Patients enrolled and
transplanted on BMT CTN
0201 study
Likely eligible but not
enrolled, transplanted
with same regimen P value b
Year of transplant <0.001
  2004 30 (6) 155 (11)
  2005 73 (15) 269 (20)
  2006 93 (19) 275 (20)
  2007 134 (27) 248 (18)
  2008 103 (21) 215 (16)
  2009 61 (12) 191 (14)
a
Patients receiving any of the four conditioning regimens (Cyclophosphamide+TBI, Cyclophosphamide+Busulfan, Fludarabine+Busulfan+ATG, 
Fludarabine+Melphalan) and cyclosporine/ tacrolimus+Methotrexate GVHD prophylaxis were classified as receiving the same regimen as 
specified by the BMT CTN 0201 protocol; patients receiving any other conditioning regimen or any other GVHD prophylaxis were excluded
b
Chi-square test (for categorical variables) or Wilcoxon rank-sum test (for continuous variables) p-values between BMT CTN 0201 patients 
(column 1) and non-BMT CTN 0201 patients with same conditioning regimen (column 2)
c
High-risk disease includes acute myeloid leukemia in third or subsequent remission or not in remission, acute lymphoblastic leukemia not in 
remission, the myelodysplastic syndrome with excess blasts in transformation, chronic myeloid leukemia in blast phase, and chronic 
myelomonocytic leukemia in any stage. All others were considered low risk.
Abbreviations: AML, Acute myelogenous leukemia; ALL, Acute lymphoblastic leukemia; CML, Chronic myeloid leukemia; MDS/ CMML, 
Myelodysplastic syndrome/ Chronic myelomonocytic leukemia; BM, bone marrow; PB, peripheral blood; KPS, Karnofsky performance score; 
CMV, cytomegalovirus; ATG, antithymocyte globulin
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Table 2
Multivariable models for Overall survival, Transplant related mortality, Relapse, Disease free survival, and 
GVHD
HR (95% CI) for non-participants
vs. study participants
P value
Overall survival1 1.08 (0.94–1.24) 0.27
Transplant related mortality2 1.08 (0.8–1.29) 0.43
Relapse3 1.22 (1.02–1.46) 0.03
Disease free survival4 1.14 (1.00–1.30) 0.05
Acute GVHD5 0.96 (0.82–1.12) 0.58
Chronic GVHD6 1.07(0.92–1.2) 0.4
1
Other significant variables include: patient age, diagnosis, disease risk, graft source, interval between diagnosis and HCT, KPS, HLA match and 
donor-recipient sex match
2
Other significant variables include: patient age, disease risk, HLA match and donor-recipient sex match, GVHD prophylaxis and use of ATG/ 
alemtuzumab
3
Other significant variables include: disease risk, donor-recipient sex match, interval between diagnosis and HCT, KPS and regimen intensity
4
Other significant variables include: patient age, disease risk, HLA match, donor-recipient sex match, interval between diagnosis and HCT and 
KPS
5
Other significant variables include graft source, HLA match, regimen intensity and use of ATG/ alemtuzumab
6
Other significant variables include: graft source, diagnosis, ethnicity, donor-recipient sex match and use of ATG/ alemtuzumab
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Table 3
Stratified analysis for Overall survival, Transplant related mortality, Relapse, Disease free survival, and 
GVHD
HR (95% CI) for non-participants vs. study
participants ; p value
Outcomes Peripheral Blood Bone Marrow
Overall survival 1.2 (0.9–1.4); 0.08 1.0 (0.8–1.2); 0.9
Transplant related mortality 1.2 (0.9–1.5); 0.2 0.9 (0.7–1.3); 0.8
Relapse 1.3 (0.9–1.6); 0.06 1.14 (0.8–1.5); 0.3
Disease free survival 1.2 ( 0.9–1.4); 0.1 1.06 (0.8–1.3); 0.6
Acute GVHD 0.9 (0.8–1.2); 0.9 0.9 (0.7–1.8); 0.6
Chronic GVHD 1.2 (0.9–1.4); 0.1 0.9 (0.7–1.2); 0.6
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